OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Allan Levey

2 Projects | 1 Researchers | $727,900 Invested

2012

Emory University

Allan Levey, MD, PhD

A phase IIa, double-blind, placebo-controlled, biomarker study of atomoxetine in subjects with mild cognitive impairment

  • Funding Amount: $447,900
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2011

Emory University

Allan Levey, MD, PhD

A phase IIa, double-blind, placebo-controlled, biomarker study of atomoxetine in subjects with mild cognitive impairment

  • Funding Amount: $280,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed